FDA
-
-
-
-
-
-
-
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
-
-
-
-
-
-
-
resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results
-
-
-
-
-
-
-
resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs
-
-
-
-
-
-
-
resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101
-
-
-
-
-
251,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All